Lyra Therapeutics Inc LYRA.OQ LYRA.O is expected to show a fall in quarterly revenue when it reports results on August 12 (estimated) for the period ending June 30 2025
The Watertown Massachusetts-based company is expected to report a 71.4% decrease in revenue to $171.25 thousand from $598 thousand a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for Lyra Therapeutics Inc is for a loss of $6.02 per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Lyra Therapeutics Inc is $23.00, about 70% above its last closing price of $6.89
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -7.50 | -6.83 | -6.00 | Beat | 12.2 |
Dec. 31 2025 | -6.26 | -6.00 | -8.00 | Missed | -33.3 |
Sep. 30 2024 | -10.46 | -11.40 | -9.00 | Beat | 21.1 |
Jun. 30 2024 | -16.42 | -16.40 | -37.00 | Missed | -125.6 |
Mar. 31 2024 | -13.32 | -13.10 | -17.50 | Missed | -33.6 |
Dec. 31 2023 | -15.75 | -11.00 | Beat | 30.2 | |
Sep. 30 2023 | -15.51 | -15.90 | -13.50 | Beat | 15.1 |
Jun. 30 2023 | -20.04 | -21.17 | -16.00 | Beat | 24.4 |
This summary was machine generated August 8 at 13:26 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)